Overview
Kehui Zhiyao develops innovative AI-driven drugs. Using its AI-driven drug development platform, it focuses on treatments for neurodegenerative diseases, cancer, and autoimmune diseases. Its core business is building an AI-driven drug discovery platform and using it to develop a range of small-molecule targeted drugs with proprietary intellectual property.
Connected profiles
Explore
More Health management products
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
科辉智药是一家人工智能驱动创新药物研发商，公司基于AI驱动的创新药研发平台，致力于解决神经退行性疾病、肿瘤和自身免疫性疾病的药物研发。公司核心业务是开发人工智能驱动的药物发现平台，以及基于该平台开发一系列具有自主知识产权的小分子靶向药物。